{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:54:28Z","timestamp":1787018068290,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2015,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Background\u2014<\/jats:title>\n                    <jats:p>Cardiac troponin and B-type natriuretic peptide (BNP) concentrations are associated with adverse cardiovascular outcome in primary prevention populations. Whether statin therapy modifies this association is poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results\u2014<\/jats:title>\n                    <jats:p>\n                      We measured high-sensitivity cardiac troponin I (hsTnI) in 12\u2009956 and BNP in 11\u2009076 participants without cardiovascular disease in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial before randomization to rosuvastatin 20 mg\/d or placebo. Nearly 92% of participants had detectable circulating hsTnI, and 2.9% of men and 4.1% of women had levels above proposed sex-specific reference limits of 36 and 15 ng\/L, respectively. hsTnI concentrations in the highest tertile were associated with a first major cardiovascular event (adjusted hazard ratio [aHR], 2.19; 95% confidence interval, 1.56\u20133.06;\n                      <jats:italic>P<\/jats:italic>\n                      for trend &lt;0.001). BNP levels in the highest tertile were also associated a first cardiovascular event (aHR, 1.94; 95% confidence interval, 1.41\u20132.68;\n                      <jats:italic>P<\/jats:italic>\n                      for trend &lt;0.001). The risk of all-cause mortality was elevated for the highest versus the lowest tertiles of hsTnI (aHR, 2.61; 95% confidence interval, 1.81\u20133.78;\n                      <jats:italic>P<\/jats:italic>\n                      for trend &lt;0.001) and BNP (aHR, 1.45; 95% confidence interval, 1.03\u20132.04;\n                      <jats:italic>P<\/jats:italic>\n                      for trend 0.02). Rosuvastatin was equally effective in preventing a first cardiovascular event across categories of hsTnI (aHR range, 0.50\u20130.60) and BNP (aHR range, 0.42\u20130.67) with no statistically significant evidence of interaction (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction=0.53 and 0.20, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\u2014<\/jats:title>\n                    <jats:p>In a contemporary primary prevention population, baseline cardiac troponin I and BNP were associated with the risk of vascular events and all-cause mortality. The benefits of rosuvastatin were substantial and consistent regardless of baseline hsTnI or BNP concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      . Unique identifier: NCT00239681.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.114.014522","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T05:46:59Z","timestamp":1427867219000},"page":"1851-1860","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":123,"title":["High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention"],"prefix":"10.1161","volume":"131","author":[{"given":"Brendan M.","family":"Everett","sequence":"first","affiliation":[{"name":"From Divisions of Cardiovascular (B.M.E., P.M.R.) and Preventive Medicine (B.M.E., R.J.G., P.M.R.), Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA; University Heart Centre Hamburg, Clinic for General and Interventional Cardiology, Germany (T.Z., S.B.); and German Centre for Cardiovascular Research Partner Site Hamburg\/L\u00fcbeck\/Kiel, Germany (T.Z., S.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Zeller","sequence":"additional","affiliation":[{"name":"From Divisions of Cardiovascular (B.M.E., P.M.R.) and Preventive Medicine (B.M.E., R.J.G., P.M.R.), Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA; University Heart Centre Hamburg, Clinic for General and Interventional Cardiology, Germany (T.Z., S.B.); and German Centre for Cardiovascular Research Partner Site Hamburg\/L\u00fcbeck\/Kiel, Germany (T.Z., S.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"From Divisions of Cardiovascular (B.M.E., P.M.R.) and Preventive Medicine (B.M.E., R.J.G., P.M.R.), Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA; University Heart Centre Hamburg, Clinic for General and Interventional Cardiology, Germany (T.Z., S.B.); and German Centre for Cardiovascular Research Partner Site Hamburg\/L\u00fcbeck\/Kiel, Germany (T.Z., S.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"From Divisions of Cardiovascular (B.M.E., P.M.R.) and Preventive Medicine (B.M.E., R.J.G., P.M.R.), Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA; University Heart Centre Hamburg, Clinic for General and Interventional Cardiology, Germany (T.Z., S.B.); and German Centre for Cardiovascular Research Partner Site Hamburg\/L\u00fcbeck\/Kiel, Germany (T.Z., S.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[{"name":"From Divisions of Cardiovascular (B.M.E., P.M.R.) and Preventive Medicine (B.M.E., R.J.G., P.M.R.), Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA; University Heart Centre Hamburg, Clinic for General and Interventional Cardiology, Germany (T.Z., S.B.); and German Centre for Cardiovascular Research Partner Site Hamburg\/L\u00fcbeck\/Kiel, Germany (T.Z., S.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm355"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009928"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1768"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1708"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht406"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.005264"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020233"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq509"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031994"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.884866"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.901413"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.089"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1896"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.192716"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.03.034"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006286"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.12.026"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.03.018"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.848473"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.3.306"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00488-3"},{"key":"e_1_3_3_24_2","first-page":"CD002003","article-title":"Beta-blockers for hypertension.","author":"Wiysonge CS","year":"2007","unstructured":"Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007:CD002003.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1899"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000450"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.129437"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.01.029"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164680"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.114.014522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:40:14Z","timestamp":1715568014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.114.014522"}},"subtitle":["Impact of Statin Therapy"],"short-title":[],"issued":{"date-parts":[[2015,5,26]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,5,26]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.114.014522"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.114.014522","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,26]]},"assertion":[{"value":"2014-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}